» Articles » PMID: 34765018

Regulatory Role of MiRNA-23a in Diabetic Retinopathy

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2021 Nov 12
PMID 34765018
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to investigate the expression of microRNA (miRNA)-23a in blood and tear samples from diabetic retinopathy (DR) patients. Blood and tear samples were obtained from 33 patients with proliferative DR. Additionally, a rat model of DR was established. Reverse transcription-quantitative PCR was used to determine vascular endothelial growth factor (VEGF) mRNA and miRNA-23a expression levels, while ELISA and western blot analysis were performed to determine protein expression levels. Bioinformatics analysis and dual luciferase reporter assay were used to predict and validate the interaction between miRNA-23a and VEGF and cell proliferative ability was assessed with the MTT assay. In comparison to control patients VEGF mRNA and protein expression levels were significantly elevated in the blood and tear samples from patients with DR, while the expression level of miRNA-23a was significantly reduced. In blood and retinal tissues from a rat model of DR, the mRNA and protein expression levels of VEGF were significantly increased, while the miRNA-23a expression level was significantly decreased relative to controls. Dual luciferase reporter assay showed that miRNA-23a bound to the 3'-untranslated region (UTR) of VEGF. Moreover, over-expression of miRNA-23a significantly reduced the expression level of VEGF and the proliferative activity of human retinal microvascular endothelial cells. The elevated VEGF expression in the blood and tears of patients with DR may be related to the reduced miRNA-23a expression. miRNA-23a may regulate microvascular growth at the retina via VEGF and contribute to DR progression.

Citing Articles

VEGFA may be a potential marker of myopic choroidal thickness and vascular density changes.

Wan T, Shi W, Liang R, Li T, Li B, Zhou X Sci Rep. 2024; 14(1):20514.

PMID: 39227639 PMC: 11372119. DOI: 10.1038/s41598-024-70616-y.


LncRNA XIST promotes neovascularization in diabetic retinopathy by regulating miR-101-3p/VEGFA.

Fu W, Ye Y, Hu F Arch Endocrinol Metab. 2024; 68:e230097.

PMID: 38739522 PMC: 11156180. DOI: 10.20945/2359-4292-2023-0097.


MicroRNA expression profiling in tears and blood as predictive biomarkers for anti-VEGF treatment response in wet age-related macular degeneration.

Yen C, Chiu C, Fang I Graefes Arch Clin Exp Ophthalmol. 2024; 262(9):2875-2884.

PMID: 38581435 DOI: 10.1007/s00417-024-06478-x.


Advances in Research Related to MicroRNA for Diabetic Retinopathy.

Luo Y, Li C J Diabetes Res. 2024; 2024:8520489.

PMID: 38375094 PMC: 10876316. DOI: 10.1155/2024/8520489.


miR-26a-5p Attenuates Oxidative Stress and Inflammation in Diabetic Retinopathy through the USP14/NF-B Signaling Pathway.

Bian J, Ge W, Jiang Z J Ophthalmol. 2024; 2024:1470898.

PMID: 38282961 PMC: 10817816. DOI: 10.1155/2024/1470898.


References
1.
Hsu Y, Hung J, Chang W, Lin Y, Pan Y, Tsai P . Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017; 36(34):4929-4942. DOI: 10.1038/onc.2017.105. View

2.
Yan Z, Hong S, Song Y, Bi M . microR-4449 Promotes Colorectal Cancer Cell Proliferation via Regulation of SOCS3 and Activation of STAT3 Signaling. Cancer Manag Res. 2021; 13:3029-3039. PMC: 8039016. DOI: 10.2147/CMAR.S266153. View

3.
Sosna T . [History of diagnosis and therapy of diabetic retinopathy]. Vnitr Lek. 2016; 62(11 Suppl 4):S136-141. View

4.
Gomaa A, Elsayed E, Moftah R . MicroRNA-200b Expression in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. Ophthalmic Res. 2017; 58(3):168-175. DOI: 10.1159/000475671. View

5.
Koleva-Georgieva D, Sivkova N, Terzieva D . Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011; 53(2):44-50. DOI: 10.2478/v10153-010-0036-8. View